Acadia Pharmaceuticals Inc. (ACAD) Stock Price
ACADStock
$19.12−7.27%52W
Market Cap$3.27B
P/E8.43x
PEG Ratio50.86
Div yield—
Beta0.91
ACAD Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-23.08%
Price vs S&P 500 (4W)-26.24%
PEG Ratio50.86
VGM Score58.61
P/E Ratio (Annual)8.43x
ACAD Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.04 | $0.18 | +317.25%(+$0.14) | |
| Q1 2026 | $0.08 | $0.02 | -75.22%(-$0.06) | |
| Q4 2025 | $0.14 | $0.14 | -4.19%(-$0.01) | |
| Q3 2025 | $0.15 | $0.42 | +189.02%(+$0.27) | |
| Q2 2025 | $0.14 | $0.16 | +15.27%(+$0.02) |
ACAD Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
ACADAcadia Pharmaceuticals Inc. | C | B | C | 2.9x | 47.0% | 91.1% | — | $19.12 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biopharmaceutical company with two core franchises in neurological and rare diseases. Its neurological franchise is anchored by NUPLAZID (pimavanserin), the first FDA-approved treatment for Parkinson's disease psychosis, while its rare disease franchise is built on DAYBUE, the first FDA-approved treatment for Rett syndrome. The company's clinical pipeline includes programs targeting Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and other neurological disorders.